Filing Details

Accession Number:
0001127602-23-028964
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-12-05 19:29:19
Reporting Period:
2023-12-01
Accepted Time:
2023-12-05 19:29:19
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1492422 Apellis Pharmaceuticals Inc. APLS Pharmaceutical Preparations (2834) 271537290
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1773588 J. Adam Townsend C/O Apellis Pharmaceuticals, Inc.
100 Fifth Avenue, 3Rd Floor
Waltham MA 02451
Chief Commercial Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2023-12-01 110,000 $15.09 186,407 No 4 M Direct
Common Stock Disposition 2023-12-01 67,557 $60.50 118,850 No 4 S Direct
Common Stock Disposition 2023-12-01 42,443 $61.31 76,407 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2023-12-01 110,000 $0.00 110,000 $15.09
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
172,500 2028-11-15 No 4 M Direct
Footnotes
  1. This is a scheduled exercise and sale from an established 10b5-1 plan.
  2. This transaction was executed in multiple trades at prices ranging from $60 - $60.995. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  3. This transaction was executed in multiple trades at prices ranging from $61 - $61.65. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  4. This includes 412 shares from 4/30/2023 ESPP purchase.
  5. This option was granted on November 16, 2018 and vests as to 25% of the shares underlying the options on the first anniversary of Mr. Townsend's date of hire, November 16, 2018, with the remaining 75% of the shares underlying the option vesting in equal monthly installments thereafter through the fourth anniversary of his date of hire, subject to continued service.
  6. This represents a stock option granted 11/16/2018 that vest as to 25% of the shares underlying the options on the first anniversary of the grant, with the remaining 75% of the shares underlying the options vesting in equal monthly installments thereafter through the fourth anniversary of the grant, subject to continued service.